Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Current Taxes (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Current Taxes for 13 consecutive years, with $65000.0 as the latest value for Q1 2025.

  • On a quarterly basis, Current Taxes fell 95.64% to $65000.0 in Q1 2025 year-over-year; TTM through Mar 2025 was $65000.0, a 95.64% decrease, with the full-year FY2024 number at $63000.0, down 94.92% from a year prior.
  • Current Taxes was $65000.0 for Q1 2025 at Anika Therapeutics, up from $63000.0 in the prior quarter.
  • In the past five years, Current Taxes ranged from a high of $1.5 million in Q1 2024 to a low of $63000.0 in Q4 2024.
  • A 4-year average of $646600.0 and a median of $814500.0 in 2022 define the central range for Current Taxes.
  • Peak YoY movement for Current Taxes: surged 67.6% in 2024, then plummeted 95.64% in 2025.
  • Anika Therapeutics' Current Taxes stood at $810000.0 in 2022, then soared by 53.09% to $1.2 million in 2023, then crashed by 94.92% to $63000.0 in 2024, then rose by 3.17% to $65000.0 in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Current Taxes are $65000.0 (Q1 2025), $63000.0 (Q4 2024), and $82000.0 (Q3 2024).